Prevalence and risk factors of development of peripheral diabetic neuropathy in type 2 diabetes mellitus in a tertiary care setting

Journal of Diabetes Investigation

Volumn 5, Issue 6, 2014, Pages 714-721

  Bansal, Dipika ^a   Gudala, Kapil ^a   Muthyala, Harini ^a   Esam, Hari Prasad ^a   Nayakallu, Ramya ^a   Bhansali, Anil ^b  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Diabetic peripheral neuropathy; Prevalence; Risk factors

Indexed keywords

GLYCOSYLATED HEMOGLOBIN;

ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DYSLIPIDEMIA; FEMALE; HUMAN; INDIAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCEPTIVE THRESHOLD; PERIPHERAL DIABETIC NEUROPATHY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; TERTIARY CARE CENTER;

EID: 84911452857     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12223     Document Type: Article

References (37)

1. Guariguata L. By the numbers: new estimates from the IDF Diabetes Atlas Update for 2012. Diabetes Res Clin Pract 2012; 98: 524-525.
2. Gudala K, Bansal D, Schifano F, et al. Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies. J Diabetes Investig 2013; 4: 640-650.
3. Boulton AJM, Gries FA, Jervell JA. Guidelines for the diagnosis and outpatient management diabetic peripheral neuropathy. Diabet Med 1998; 24: 55-65.
4. Sumner CJ, Sheth S, Griffin JW, et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003; 60: 108-111.
5. Candrilli SD, Davis KL, Kan HJ, et al. Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy. J Diabetes Complications 2007; 21: 306-314.
6. Herman WH, Kennedy L. Underdiagnosis of peripheral neuropathy in type 2 diabetes. Diabetes Care 2005; 28: 1480-1481.
7. Herman WH, Eastman RC. The effects of treatment on the direct costs of diabetes. Diabetes Care 1998; 21: C19-C24.
8. Happich M, John J, Stamenitis S, et al. The quality of life and economic burden of neuropathy in diabetic patients in Germany in 2002-results from the Diabetic Microvascular Complications (DIMICO) study. Diabetes Res Clin Pract 2008; 81: 223-230.
9. Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Pain Med 2008; 9: 660-674.
10. Dworkin RH, Malone DC, Panarites CJ, et al. Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs. J Pain 2010; 11: 360-368.
11. Rani PK, Raman R, Rachapalli SR, et al. Prevalence and risk factors for severity of diabetic neuropathy in type 2 diabetes mellitus. Indian J Med Sci 2010; 64: 51-57.
12. Pradeepa R, Rema M, Vignesh J, et al. Prevalence and risk factors for diabetic neuropathy in an urban south Indian population: the Chennai Urban Rural Epidemiology Study (CURES-55). Diabet Med 2008; 25: 407-412.
13. Raman R, Gupta A, Krishna S, et al. Prevalence and risk factors for diabetic microvascular complications in newly diagnosed type II diabetes mellitus. Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetic Study (SN-DREAMS, report 27). J Diabetes Complications 2012; 26: 123-128.
14. Boulton AJ, Armstrong DG, Albert SF, et al. Comprehensive foot examination and risk assessment: a report of the task force of the foot care interest group of the American Diabetes Association, with endorsement by the American Association of Clinical Endocrinologists. Diabetes Care 2008; 31: 1679-1685.
15. Ghosal S, Stephens J, Mukherjee A. Quantitative vibration perception threshold in assessing diabetic neuropathy: is the cut-off value lower for Indian subjects? [Q-VADIS Study]. Diabetes Metab Syndr 2012; 6: 85-89.
16. Young MJ, Breddy JL, Veves A, et al. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care 1994; 17: 557-560.
17. Yousif AR. Predicting microvascular complications in diabetic patients. Iraqi J Med Sci 2011; 9: 195-205.
18. Morkrid K, Ali L, Hussain A. Risk factors and prevalence of diabetic peripheral neuropathy: a study of type 2 diabetic outpatients in Bangladesh. Int J Diabetes Dev Ctries 2010; 30: 11-17.
19. Katulanda P, Ranasinghe P, Jayawardena R, et al. The prevalence, patterns and predictors of diabetic peripheral neuropathy in a developing country. Diabetol Metab Syndr 2012; 4: 21.
20. Cardoso CR, Salles GF. Predictors of development and progression of microvascular complications in a cohort of Brazilian type 2 diabetic patients. J Diabetes Complications 2008; 22: 164-170.
21. Lu B, Yang Z, Wang M, et al. High prevalence of diabetic neuropathy in population-based patients diagnosed with type 2 diabetes in the Shanghai downtown. Diabetes Res Clin Pract 2010; 88: 289-294.
22. Rubino A, Rousculp MD, Davis K, et al. Diagnosis of diabetic peripheral neuropathy among patients with type 1 and type 2 diabetes in France, Italy, Spain, and the United Kingdom. Prim Care Diabetes 2007; 1: 129-134.
23. Kasim K, Amar M, Sadek AAE, et al. Peripheral neuropathy in type-II diabetic patients attending diabetic clinics in Al-Azhar University Hospitals, Egypt. Int J Diabetes mellitus 2009; 2: 20-23.
24. Fedele D, Comi G, Coscelli C, et al. A multicenter study on the prevalence of diabetic neuropathy in Italy. Italian Diabetic Neuropathy Committee. Diabetes Care 1997; 20: 836-843.
25. Abougalambou SS, Abougalambou AS. Explorative study on diabetes neuropathy among type II diabetic patients in Universiti Sains Malaysia Hospital. Diabetes Metab Syndr 2012; 6: 167-172.
26. Shaw JE, Hodge AM, de Courten M, et al. Diabetic neuropathy in Mauritius: prevalence and risk factors. Diabetes Res Clin Pract 1998; 42: 131-139.
27. Gregg EW, Sorlie P, Paulose-Ram R, et al. Prevalence of lower-extremity disease in the US adult population >=40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey. Diabetes Care 2004; 27: 1591-1597.
28. Masson EA, Hunt L, Gem JM, et al. A novel approach to the diagnosis and assessment of symptomatic diabetic neuropathy. Pain 1989; 38: 25-28.
29. Dyck PJ, Kratz KM, Lehman KA, et al. The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests. Neurology 1991; 41: 799-807.
30. Tapp RJ, Shaw JE, de Courten MP, et al. Foot complications in Type 2 diabetes: an Australian population-based study. Diabet Med 2003; 20: 105-113.
31. Bruce SG, Young TK. Prevalence and risk factors for neuropathy in a Canadian First Nation community. Diabetes Care 2008; 31: 1837-1841.
32. Davies M, Brophy S, Williams R, et al. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006; 29: 1518-1522.
33. Kamenov ZA, Parapunova RA, Georgieva RT. Earlier development of diabetic neuropathy in men than in women with type 2 diabetes mellitus. Gend Med 2010; 7: 600-615.
34. The DCCT Research Group. Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. Diabetes 1988; 37: 476-481.
35. Gregersen G. Diabetic neuropathy: influence of age, sex, metabolic control, and duration of diabetes on motor conduction velocity. Neurology 1967; 17: 972-980.
36. Aaberg ML, Burch DM, Hud ZR, et al. Gender differences in the onset of diabetic neuropathy. J Diabetes Complications 2008; 22: 83-87.
37. Tanaka S, Iimuro S, Yamashita H, et al. Predicting macro- and microvascular complications in type 2 diabetes: The Japan Diabetes Complications Study/the Japanese elderly diabetes intervention trial risk engine. Diabetes Care 2013; 36: 1193-1199.